SO My DR SAYS YOUR THE GUY BIG INTO STOCKS WHAT IS THE IDEA FOR NEXT YEAR... HUGE PAUSE... I REALLY HAD NO IDEA!> AI I said.. He seemed unconvinced.. I said IBM has been buying up AI companies, six of them.. he raised an eyebrow... NVDA stands to benefit with their Ai storage... He stood back... Like This? Voice tech developer SoundHound AI sees stock rally 56% Dr's!
SIT BACK AND ENJOY THE RIDE-! Ardelyx, Inc. (ARDX)- SHE'S SPIKING! NasdaqGM - NasdaqGM Real Time Price. 2.8350+0.3050 (+12.0553%)<-------------- As of 02:56PM EST.
PDSB ($12.6 to $13.30 on light volume. Will KALA take out $50 in AH? I don’t know what it does or why it’s been screaming. Shorts have tried to reign it in to no avail.
... YOU MAY OF NOTICED I GAVE A TINY TIP ON KALA... I think I said wow kala.. that was $30 ago.. no idea what's going on. Scary.
PDSB> Ted my computer Safari is freezing up so I can't scroll very much I don't see the last time PDSB raised money I would get the hell out. This is Head & Neck cancer that's a bitch of a sub sector...
Stoney off S/A news. “ PDS Biotechnology (NASDAQ:PDSB) reportedupdated data from an ongoing phase 2 trial of PDS0101 in combination with chemoradiotherapy to treat patients with cervical cancer. The company said 9 out of 9 patients treated with PDS0101 and standard-of-care chemoradiotherapy (CRT) in the study, dubbed IMMUNOCERV, had a clinical response with tumor shrinkage >60% at mid-point evaluation by MRI.”
VERY EMOTIONAL TIMES. END OF YEAR. END OF THREAD. We have fostered a safe place for smart people.Not so safe for dummies. We have done so much now it's time to rest and fix our teeth.
This was the PR today anal, cervical, head and neck, vaginal, and vulvar cancers<-- Just not cancers i want to have or treat they all seem tricky... PDS Biotechnology announces interim data in a Phase 2 trial of PDS0101 08:03 PDSB PDS Biotechnology announced expanded interim data in a Phase 2 clinical trial investigating the PDS0101-based triple combination therapy in advanced human papillomavirus, or HPV, -positive cancers. The triple combination of PDS0101 with the tumor-targeting IL-12 fusion protein M9241, and bintrafusp alfa, a bifunctional fusion protein targeting two independent immunosuppressive pathways, is being studied in CPI-naive and CPI-refractory patients with advanced HPV-positive anal, cervical, head and neck, vaginal, and vulvar cancers. The triple combination Phase 2 trial is being conducted at the Center for Cancer Research, or CCR, at the National Cancer Institute, or NCI, one of the Institutes of the National Institutes of Health. All patients in the study had failed prior treatment with chemotherapy and 90% had failed radiation treatment. The interim efficacy data involves 37 HPV16-positive evaluable patients, including 29 patients who have, in addition, failed treatment with CPIs. Highlights of the expanded interim data are as follows and are consistent with the results presented at American Society of Clinical Oncology, or ASCO, Annual Meeting 2022 and prior interim data announced in October: Both M9241 and bintrafusp alfa are owned by Merck KGaA, Darmstadt, Germany, and its affiliates.